title: [Naproxen-induced pseudoporphyria].
abstract: A 12 year old boy developed scars at light-exposed areas following long-term therapy with naproxen for rheumatoid arthritis. Erythrocyte and urine porphyrin levels were not increased, and there was no evidence of increased photosensitivity. Pseudoporphyria is reported in 10-20% of those treated with naproxen for > 4 weeks. As compared to other nonsteroidal anti-inflammatory agents, the specific risk for naproxen is increased about 6fold. While the underlying abnormality has not been elucidated, formation of phototoxic metabolites in a subgroup of genetically predisposed individuals has been suggested as the most likely mechanism. Both dermatologists and rheumatologists should be aware of the risk of naproxen-induced pseudoporphyria and discontinue therapy early in order to avoid scar formation in light-exposed areas.
authors.affiliation: Klinik und Poliklinik für Dermatologie und Venerologie, Bereich Pädiatrische Dermatologie, Universitätsklinikum Hamburg-Eppendorf.
authors.forename: J M
authors.initials: JM
authors.lastname: Maerker
authors.forename: A
authors.initials: A
authors.lastname: Harm
authors.forename: I
authors.initials: I
authors.lastname: Foeldvari
authors.forename: P H
authors.initials: PH
authors.lastname: Höger
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002648:Child; D006801:Humans; D008297:Male; D009288:Naproxen / Q000008:administration & dosage / Q000009:adverse effects*; D011164:Porphyrias / Q000139:chemically induced*; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D009288:Naproxen